There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination

dc.contributor.authorZimet, Gregory D.
dc.contributor.authorOsazuwa-Peters, Nosayaba
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2019-12-26T15:30:59Z
dc.date.available2019-12-26T15:30:59Z
dc.date.issued2019
dc.description.abstractIt has been over 10 y since the first HPV vaccines were licensed and introduced in a number of countries around the world. As only the second vaccine (after hepatitis B) that prevents an infection that can lead to the development of cancer, HPV vaccine occupies an important position in our armamentarium of vaccines yet remains underutilized. The number of national HPV vaccination programs has increased steadily; as of June 2017, 91 countries had introduced national HPV vaccination programs,1 with that number now over 100. Over the past 10+ y, several modifications have been made to the vaccination regimen (e.g., moving from three to two doses if the first dose is administered before age 15 y), in the type of vaccine available (e.g., introduction of the 9-valent vaccine), and in the target of vaccination (e.g., many countries have shifted from female-only to gender-neutral vaccination). There is great variability across the globe in terms of HPV vaccination policies and accompanying barriers to the implementation and/or sustainability of programs. It is well known, for instance, that Japan’s initial success with vaccination was undermined by several factors, leading to a precipitous drop in vaccination rates, with little subsequent recovery.2 Other countries, such as the U.S.,3 have struggled to achieve vaccination goals, and still others have faced setbacks but with good recovery (e.g., Denmark and Ireland).4,5 At the same time, many countries, including China,6 still have not implemented national vaccination programs, with the cost of vaccines presenting a significant obstacle, particularly for those countries that are not eligible for reduced pricing through Global Alliance for Vaccines and Immunisation (GAVI) or other mechanisms. Other countries, such as Malaysia, Rwanda, Australia, and the U.K., have achieved sustained high levels of vaccination.7–10 Unwarranted fears about HPV vaccine and the proliferation of misinformation, particularly via social media, have proven to be significant and widespread obstacles to achieving and maintaining high vaccination ratesen_US
dc.identifier.citationZimet, G. D., & Osazuwa-Peters, N. (2019). There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination. Human vaccines & immunotherapeutics, 15(7-8), 1459–1464. doi:10.1080/21645515.2019.1640559en_US
dc.identifier.urihttps://hdl.handle.net/1805/21580
dc.language.isoen_USen_US
dc.publisherTaylor & Francisen_US
dc.relation.isversionof10.1080/21645515.2019.1640559en_US
dc.relation.journalHuman Vaccines & Immunotherapeuticsen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourcePMCen_US
dc.subjectHPVen_US
dc.subjectVaccinesen_US
dc.subjectCervical canceren_US
dc.subjectOropharyngeal canceren_US
dc.titleThere's Much Yet to be Done: Diverse Perspectives on HPV Vaccinationen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
khvi-15-7-8-1640559.pdf
Size:
657.81 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: